Crescent Biopharma (CBIO) Competitors $15.89 +0.34 (+2.19%) As of 07/3/2025 12:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesSEC FilingsSustainabilityTrendsBuy This Stock CBIO vs. CRIS, SABS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Curis SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Curis (NASDAQ:CRIS) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Is CRIS or CBIO more profitable? Crescent Biopharma has a net margin of 0.00% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Curis-376.08% N/A -97.14% Crescent Biopharma N/A -293.92%-206.20% Do institutionals & insiders believe in CRIS or CBIO? 30.0% of Curis shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 5.5% of Curis shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, CRIS or CBIO? Crescent Biopharma has lower revenue, but higher earnings than Curis. Crescent Biopharma is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.91M1.76-$43.39M-$6.23-0.30Crescent Biopharma$10K31,064.95-$37.88M-$46.00-0.35 Which has more risk & volatility, CRIS or CBIO? Curis has a beta of 3.6, suggesting that its share price is 260% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Does the media prefer CRIS or CBIO? In the previous week, Curis had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for Curis and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.58 beat Curis' score of 0.20 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CRIS or CBIO? Curis currently has a consensus price target of $17.00, indicating a potential upside of 823.91%. Crescent Biopharma has a consensus price target of $25.00, indicating a potential upside of 57.33%. Given Curis' higher probable upside, research analysts clearly believe Curis is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 SummaryCuris beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.65M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%4.01%P/E RatioN/A9.1027.6120.24Price / Sales31,064.95680.44416.87118.48Price / CashN/A158.5936.8958.10Price / Book1.934.588.035.67Net Income-$37.88M$31.34M$3.18B$249.21M7 Day Performance-0.06%3.25%2.93%3.28%1 Month PerformanceN/A7.08%3.75%5.55%1 Year PerformanceN/A0.17%35.20%21.09% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma3.3099 of 5 stars$15.89+2.2%$25.00+57.3%N/A$310.65M$10K0.0026News CoverageHigh Trading VolumeCRISCuris2.8914 of 5 stars$2.18+1.4%$17.00+679.8%-70.6%$22.80M$10.91M-0.3560News CoverageSABSSAB Biotherapeutics3.0563 of 5 stars$1.75-0.6%$13.25+657.1%-41.0%$16.12M$1.32M-0.47140News CoveragePositive NewsGap UpBOLTBolt Biotherapeutics2.99 of 5 stars$5.65+0.9%$50.00+785.0%-58.7%$10.85M$7.69M-0.1790News CoveragePositive NewsMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.5225 of 5 stars$277.37+1.8%$309.22+11.5%-3.6%$148.89B$33.42B25.2628,000GILDGilead Sciences4.8432 of 5 stars$107.13+0.9%$110.55+3.2%+67.1%$133.15B$28.75B22.5417,600Positive NewsInsider TradeVRTXVertex Pharmaceuticals4.7263 of 5 stars$445.42+0.4%$513.14+15.2%-3.3%$114.34B$11.10B-113.596,100Positive NewsREGNRegeneron Pharmaceuticals4.9548 of 5 stars$526.47+2.8%$836.48+58.9%-46.8%$56.85B$14.20B13.4115,106ALNYAlnylam Pharmaceuticals4.2984 of 5 stars$322.97+3.1%$323.30+0.1%+33.5%$42.07B$2.25B-154.372,230Analyst UpgradeBIIBBiogen4.9303 of 5 stars$126.65+1.5%$188.19+48.6%-41.0%$18.54B$9.68B12.497,605 Related Companies and Tools Related Companies Curis Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CBIO Stock Alerts